CAS 10391-08-9: macrocalin A

Macrocalin A is an antibiotic, which is derived from Streptomyces bacteria with bactericidal activity. The source of this compound, Streptomyces, is a genus of Gram-positive bacteria known for its rich production of bioactive secondary metabolites. The mode of action of Macrocalin A involves inhibition of cell wall synthesis in target bacteria, specifically by binding to peptidoglycan precursors, thus preventing their incorporation into the cell wall structure. This results in cell lysis and ultimately, bacterial death. Macrocalin A is utilized in the treatment of various bacterial infections, particularly those caused by Gram-positive pathogens. Its broad-spectrum activity makes it a valuable tool in combating resistant strains and is often employed in settings where multidrug-resistant organisms are prevalent. Research continues to explore its efficacy in combination therapies to enhance antibacterial strategies and extend its applications to other resistant bacterial species. As antibiotic resistance continues to rise, Macrocalin A represents a significant asset in the development of new treatment regimens for infectious diseases.